S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:CMPI

Checkmate Pharmaceuticals (CMPI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$10.50
$10.50
50-Day Range
$10.37
$10.50
52-Week Range
$2.00
$10.50
Volume
N/A
Average Volume
142,261 shs
Market Capitalization
$231.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CMPI stock logo

About Checkmate Pharmaceuticals Stock (NASDAQ:CMPI)

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CMPI Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
See More Headlines
Receive CMPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkmate Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CMPI
Fax
N/A
Employees
28
Year Founded
N/A

Profitability

Net Income
$-61,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.50 per share

Miscellaneous

Free Float
8,242,000
Market Cap
$231.40 million
Optionable
Not Optionable
Beta
-4.81
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Robert F. Dolski (Age 52)
    CFO & Principal Accounting Officer
    Comp: $411.7k
  • Dr. James E. Wooldridge M.D. (Age 56)
    Chief Medical Officer
    Comp: $567.29k
  • Mr. Alan Bash (Age 50)
    Pres, CEO & Director
  • Dr. Arthur M. Krieg M.D. (Age 65)
    Ph.D., Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director
  • Ms. Katherine A. Eade (Age 48)
    Gen. Counsel
  • Dr. Kleem Chaudhary Ph.D. (Age 46)
    Chief Bus. Officer

CMPI Stock Analysis - Frequently Asked Questions

How were Checkmate Pharmaceuticals' earnings last quarter?

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.02.

What other stocks do shareholders of Checkmate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkmate Pharmaceuticals investors own include Oak Street Health (OSH), Adobe (ADBE), Berkshire Hathaway (BRK.A), Lockheed Martin (LMT), Tesla (TSLA), Acutus Medical (AFIB), BigCommerce (BIGC), Freeline Therapeutics (FRLN), Rocket Companies (RKT) and Agnico Eagle Mines (AEM).

When did Checkmate Pharmaceuticals IPO?

Checkmate Pharmaceuticals (CMPI) raised $75 million in an initial public offering on Friday, August 7th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets served as the underwriters for the IPO and BTIG was co-manager.

This page (NASDAQ:CMPI) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners